Novavax Is Preselling Its Coronavirus Vaccine, but at What Price?

Novavax (NASDAQ: NVAX) reached an agreement to sell 1.1 million doses of its coronavirus vaccine to COVAX, an organization led by the Coalition of Epidemic Preparedness Innovations, Gavi, and the World Health Organization. But figuring out how much that might benefit the biotech is difficult given the lack of financial details for the deal. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal and the prospects for Novavax's vaccine.

Continue reading

Source Fool.com